TMO surges to $690, but new DCF pegs intrinsic value at $421, signaling severe overvaluation.

What happened

On October 19, 2026, GuruFocus published a DCF analysis estimating Thermo Fisher Scientific's intrinsic value at $421 per share, contrasting sharply with the market price of $690. The deep value master report, previously based on a price of $501, had already rated TMO a WAIT with a trim threshold above $575 and an attractive entry at $470. Since that report, the stock has climbed 38% to $690, exceeding even the bull case implied value of $575 and the trim level. The new DCF figure of $421 falls below the master report's bear case of $440, reinforcing that the market has priced in an overly optimistic scenario. This combination indicates that the risk/reward has deteriorated further, and the prior WAIT stance is no longer sufficient.

Implication

Given the price surge to $690, investors should trim positions to manage risk, as the DCF suggests over 39% downside to fair value. The deep value report's trim above $575 is now clearly breached, and even its bull case of $575 is below market. Academic/government funding risks and tariff/FX margin pressures remain unresolved, making the fundamentals fragile. The Clario acquisition adds execution risk and leverage, which is not yet reflected in the price. Waiting for a better entry near $470 or lower, as per the deep value report, is prudent, but current levels offer poor risk/reward.

Thesis delta

The prior WAIT rating at $501 was based on limited upside and a trim threshold of $575. With the stock at $690, well above that threshold, and a new DCF analysis suggesting fair value of $421 (below the bear case), the thesis shifts from WAIT to a clear SELL or aggressive trim. Investors should exit or reduce positions until the price falls closer to the attractive entry of $470 or fundamental risks improve.